Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit~* Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening visit.~Exclusion criteria:~* Screening HbA1c \< 7.0% and \> 10.0%~* Fasting plasma glucose at screening \> 250 mg/dL (\> 13.9 mmol/L)~* Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening, previous use of insulin~* Participants who usually did not eat breakfast~* Type 1 diabetes mellitus~* Body Mass Index (BMI) ≤ 20 kg/m\^2 and \> 40 kg/m\^2~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method~* Amylase and/or lipase \> 3 times the upper limit of the normal laboratory range ( ULN) at screening~* Alanine aminotransferase (ALT) \> 3 ULN at screening~* Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes)~* Any contra-indication related to metformin~* Any previous treatment with lixisenatide~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixisenatide Main Meal (Type: EXPERIMENTAL): Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.
- Lixisenatide Breakfast (Type: ACTIVE_COMPARATOR): Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).